Bio-Rad BIO has been facing the impact of funding issues in the biopharmaceutical or BioPharma space, macroeconomic headwinds and competitive pressure. The stock carries a Zacks Rank #4 (Sell ...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly.

RBC Capital lowered the firm’s price target on Bio-Rad (BIO) to $409 from $430 and keeps an Outperform rating on the shares as part of a ...

Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms.

Strengthen Your Lab's Quality Control System Introduction Choosing the right quality control (QC) system for your laboratory ...

A federal jury Monday awarded the former general counsel of Bio-Rad Laboratories $8 million in back pay and damages — which will increase to $11 million — for whistleblower retaliation involving ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on April 1 and set a price target of ...

TC20 Automated Cell Counter from Bio-Rad Whole Gel Eluter and Mini Whole Gel Eluter from Bio-Rad High Credibility: This website adheres to all nine standards of credibility and transparency.

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Foresight™ Pro 45 cm inner diameter (ID) ...

Company Information Key Financials (last Fiscal Year) Profit Ratios Earnings Per Share (last Fiscal Year) Total Return © 2025 Fortune Media IP Limited. All Rights ...